Table 2 Ever use of different groups of non-steroidal anti-inflammatory drugs (NSAID) in the two time periods
From: Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control study
Five years before one index date | Until 1 year before the index date | |||||||
|---|---|---|---|---|---|---|---|---|
Odds ratios for ever/never use | Cases ( n =1141) | Controls ( n =7954) | OR (95%CI) | Adjusted OR (95%CI) a | Cases ( n =1141) | Controls ( n =7954) | OR (95%CI) | Adjusted OR (95%CI) a |
Acetic Acid derivatives | 249 (21.8%) | 1747 (22.0%) | 0.99 (0.85–1.16) | 0.96 (0.82–1.13) | 409 (35.9%) | 2762 (34.7%) | 1.06 (0.92–1.21) | 0.99 (0.86–1.14) |
Aspirin and derivatives | 236 (20.68%) | 1601 (20.1%) | 1.03 (0.88–1.22) | 0.95 (0.81–1.13) | 267 (23.4%) | 1813 (22.8%) | 1.04 (0.89–1.21) | 0.95 (0.81–1.12) |
Coxibs | 45 (3.94%) | 353 (4.4%) | 0.87 (0.63–1.22) | 0.80 (0.56–1.11) | 47 (4.1%) | 356 (4.5%) | 0.91 (0.66–1.26) | 0.82 (0.58–1.16) |
Fenamates | 14 (1.2%) | 93 (1.2%) | 1.06 (0.59–1.89) | 1.02 (0.56–1.86) | 43 (3.8%) | 267 (3.4%) | 1.14 (0.81–1.60) | 1.09 (0.77–1.55) |
Other NSAIDs | 19 (1.7%) | 86 (1.1%) | 1.57 (0.95–2.60) | 1.43 (0.85–2.43) | 44 (3.9%) | 219 (2.75%) | 1.44 (1.03–2.01) | 1.41 (1.0–1.99) |
Oxicams | 24 (2.1%) | 234 (2.9%) | 0.71 (0.46–1.08) | 0.67 (0.43–1.03) | 62 (5.4%) | 480 (6.0%) | 0.89 (0.68–1.18) | 0.83 (0.62–1.10) |
Propionic acid derivatives | 307 (26.9%) | 2023 (25.4%) | 1.08 (0.94–1.25) | 1.06 (0.92–1.23) | 574 (50.3%) | 3715 (46.7%) | 1.17 (1.03–1.32) | 1.12 (0.98–1.28) |
High-dose aspirin | 30 (2.6%) | 208 (2.6%) | 1.0 (0.67–0.48) | 0.91 (0.61–1.35) | 53 (4.6%) | 314 (3.9%) | 1.19 (0.88–1.61) | 1.10 (0.81–1.50) |
